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ABSTRACT 
 
Chemical, pharmacokinetic, and pharmacodynamics properties are available in the package 
inserts of every Food and Drug Administration (FDA) approved prescription drug, including all 
available chemotherapy drugs. These inserts follow a specific format imposed by the FDA. 
Whether chemotherapy drugs are administered via the parenteral route or alimentary tract, a 
significant factor affecting their bioavailability, elimination, and consequently, the drug’s 
effectiveness and potency, is its state of aqueous solubility. Water solubility has always lent itself 
poorly to the different predictive and experimental measures employed in the determination of a 
useful quantitative assessment. In this project, we first built a chemical structure-based searchable 
database for 85 FDA approved chemotherapy drugs and then used Bio-Rad’s KnowItAll® 
Informatics suite to focus on the drugs pH-dependent water solubility prediction. We compared 
the predicted values for water solubility to the available values reported in the drug inserts, 
testing the practical utility and the predictive ability of our model in reporting such a clinically 
relevant, underreported pharmacokinetic parameter. A relational cancer drug database (MySQL) 
was created to further facilitate analysis and/or prediction of a chemotherapy compound’s 
missing pharmacokinetic properties. 
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INTRODUCTION 
 
ince 2003, Wesley College (Wesley; www.wesley.edu) undergraduates in the Science, Technology, 
Engineering, and Mathematics (STEM) related fields of biological chemistry, biology, environmental 
studies, mathematics, and medical technology are afforded an opportunity to participate in biomedically-
related research projects (D’Souza, Dwyer et al., 2011; D’Souza and Wang, 2012) through an Institutional 
Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) grant funded by the National 
Center for Research Resources (NCRR) at the National Institutes of Health (NIH). In 2012, this federally funded 
national INBRE program, contrived to augment and strengthen the IDeA-eligible state's biomedical research 
capacity, was assigned to the National Institute of General Medical Sciences at NIH (NIGMS). 
 
In Delaware (DE), the University of Delaware (UD) leads and administers the DE-INBRE 
(www.inbre.udel.edu) program. The other partners in this project include the Christiana Care Health System 
(Christiana), Delaware State University (DSU), Delaware Technical & Community College (DTCC), the 
Nemours/A.I. DuPont Hospital for Children (Nemours), and Wesley College. 
 
 
 
S 
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EVOLUTION OF TEAM DEVELOPMENT OF PHARMACEUTICAL DATABASES AT WESLEY 
 
In the mid-1990s, big pharma got involved with the management, searching, and integration of large 
molecular data files to discover, design, and optimize a diverse library of biology active compounds (Banville, 
2006). Such innovative and efficient Computer-Aided Drug Design (CADD) strategies exploit state-of-the-art 
computational technologies (in silico) to accelerate the drug development and structure optimization process 
(Mandal et al., 2009). Quantitative structure-activity relationships (QSAR) utilizing in silico tools are now typically 
employed to understand the relationships between biological activity and chemical drug structure (Ekins et al., 
2007). 
 
To introduce core competencies and to increase awareness in biomedical, chemical, and health informatics, 
students at Wesley get exposed to such cutting-edge computing fields via interdisciplinary undergraduate research 
projects in chemistry, biology, electronic data-mining, computer programming, statistics, and medicine (D’Souza 
and Koyoshi, 2008; D’Souza et al., 2009; D’Souza et al., 2009; D’Souza and AlAbed, 2010; D’Souza and Gerges, 
2010; D’Souza, AlAbed et al., 2011). Numerous public or commercial computational tools and databases are 
available to identify mechanistic patterns that can provide structure-activity relationships of biologically active 
molecules for the early detection of toxicity prior to significant human exposure (Rusyn and Daston, 2010; Reddy et 
al. 2011). One such commercial solution is the Bio-Rad’s KnowItAll® Informatics System for spectroscopy, 
cheminformatics, in silico ADME/Tox (absorption, distribution, metabolism, excretion and toxicity, or ADMET) 
prediction, and lead optimization (D’Souza, 2005; D’Souza, 2007). 
 
Since 1968, the Food and Drug Administration (FDA) approved drug package inserts profile drugs by 
chemical structure and contain high quality prescribing, safety, efficacy, consumer self-care, and detailed product 
information about the US marketed pharmaceuticals (Hartgraves, 2002; Donohue, 2006; Shrank and Avorn, 2007; 
Watson and Barash, 2009; de Leon, 2011). These publically available inserts, containing important protocol-
required clinical data, are created by unrelated pharmaceutical companies and, as a result, tend to be very different in 
the way the required information is reported (Shrank and Avorn, 2007; D’Souza and Koyoshi, 2008; Zarin and Tse, 
2008; D’Souza et al., 2009; D’Souza et al., 2009; Watson and Barash, 2009; D’Souza and AlAbed, 2010; D’Souza 
and Gerges, 2010; D’Souza, AlAbed et al., 2011; de Leon, 2011). 
 
In 2007 using the chemical, pharmacokinetic, and pharmacodynamic data obtained from the FDA drug 
profiles and together with the KnowItAll
®
 Informatics System, we created an FDA Consumer Drug Database
©
 
containing 75 orally administered drugs (D’Souza and Koyoshi, 2008). This database is available as one of many 
training datasets for benchmarking experiments in drug discovery and for interpreting the success and building of 
ADME/Tox predictive models (KnowItAll
®
 Informatics System – Experimental ADME/Tox Databases, 2008). We 
found that amongst the various drug companies, there was a significant lack of uniformity in the reporting of clinical 
data within the FDA-mandated consumer drug information packets (D’Souza and Koyoshi, 2008; D’Souza et al. 
2009; D’Souza et al. 2009). 
 
A second project evaluated fourteen chemical and pharmacological properties from 85 FDA cancer drug 
profiles (D’Souza and AlAbed, 2010; D’Souza, AlAbed et al., 2011). The drugs were selected on the basis of the 
their published chemical structure and, a cancer drug database (shown in Figure 1) containing this information was 
created utilizing the KnowItAll
®
 Informatics System (D’Souza, AlAbed et al., 2011). We discovered that here too 
there were substantial deficiencies in the reporting of some clinical parameters that are essential for the dosage 
calculations and for the safety and effectiveness of the FDA approved cancer drugs (D’Souza and AlAbed, 2010; 
D’Souza and Gerges, 2010; D’Souza, AlAbed et al., 2011). These important findings were recently featured on the 
Word on Health blog (SRxA’s Word on Health, 2010) of the Strategic Pharmaceutical Advisors (SRxA). 
 
However, public usage of the information from our cancer drug database was heavily limited due to access 
of the underlying commercial platform. Hence, using the information from the KnowItAll
®
 Informatics System as a 
starting point, a relational cancer drug database (MySQL) was created as a result of a collaborative effort of 
researchers from Wesley College and Center for Bioinformatics & Computational Biology (CBCB) at the University 
of Delaware (D’Souza, AlAbed et al., 2011). One purpose of this expanded project is to further facilitate the analysis 
and/or the prediction of the chemotherapy compound’s missing pharmacokinetic properties. 
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Figure 1:  Screen Print Example From Bio-Rad Knowitall® Informatics System Output 
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DESIGN OF A PUBLIC CANCER DRUG DATABASE AND THE PREDICTION OF AQUEOUS DRUG 
SOLUBILITY 
 
In order to accomplish universal acceptance of a public cancer drug database, our goal was to design the 
database, load all existing compounds, and implement a web application that will allow users to view and edit the 
content of the database. The 85 FDA cancer drugs were initially chosen on the basis of the presence of at least one 
carbonyl containing functional group in the drugs chemical structure and on the availability of documented 
physicochemical parameters. We first designed a schema of the normalized relational database (D’Souza, AlAbed et 
al., 2011). The database design was aiming to achieve detailed information about each compound, their properties, 
as well as the methods that were used to collect those properties. 
 
The information collected for each drug was first tabulated within a database created using the KnowItAll
® 
ADME/Tox Edition (Figure 1). This program gave an output of the drug that included the data about the different 
properties, such as the pH profile, and the source of the data itself. From that output, we collected our data and then 
began the process of editing the preexisting MySQL-database (D’Souza, AlAbed et al., 2011). We took the pH 
profiles for each drug and saved it into a separate file in order to add it to the database. When adding new data to this 
database, the schema for the database itself had to be modified (Figure 2, changes are in bold). 
 
Figure 2:  E/R Diagram For The Cancer Drug Database 
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As a result of this work, a relational database has now been created (Figures 3-5). The database interface 
allows the user to add new possible measurements of the compound properties coupled with the detailed description 
of the each method (Figure 3), to browse among stored compounds and to visualize the structure (Figures 4, 5), and 
to import new compounds and their corresponding structures (Figure 4). 
 
The visualization of the compounds is accomplished by using Jmol, an interactive web browser applet. 
Jmol is a free, open source molecule viewer for students, educators, and researchers in chemistry and biochemistry. 
It is also a cross-platform, running on Windows, Mac OS X, and Linux/Unix systems. 
 
 
Figure 3:  Screen-Shot Of The Cancer Drug Database GUI View (New Method Of Measurement Addition) 
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Figure 4:  Screen-Shot Of The Cancer Drug Database GUI View (New Compound Addition) 
 
 
 
Figure 5:  Screen-Shot Of The Cancer Drug Database GUI View (Visualization Of The Existing Compounds In The 
Database) 
 
Hence, to aid in the use of determining missing clinical data, we have created a viable option that utilizes 
in-silico tools to predict missing pharmacokinetic parameters. This gives us the ability to enhance better drug 
delivery in the human body. In order to address pH-sensitive drug pharmacokinetics, we show (below) the predictive 
ability of our model using five examples of well-known cancer drugs that contain at least one carbonyl group in their 
chemical drug structure. 
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CLINICAL/PHARMACOKINETICS CORRELATION AS APPLIED TO OUR PREDICTIVE MODEL 
 
Taxol
®
 
 
As an indicated first line or adjuvant chemotherapy for solid tumors like ovarian carcinoma, breast 
carcinoma or non-small cell lung carcinoma, Taxol
® 
(paclitaxel), intravenously administered, targets these tumors by 
its inherent very high bioavailability. Due to its low water solubility and high protein binding capacity, it directly 
redistributes from the intravascular compartment into peripheral compartment leading to high-targeted therapy on 
the intended solid tumor cancer cells. The solubility reported in experimental and in vitro models is mirrored in our 
in-silico predictions (illustrated in Figure 6), thus indicating the accuracy by which pharmacokinetic properties of 
such drugs can be predicted in anticipation of its utility. At the normal blood pH (7.4), Taxol
®
 is essentially not 
water soluble, a function that is predicted by our in-silico model using the functional groups’ chemical 
characteristics of its parent compound. Extrapolating our model into its predictive utility, the selection of similar 
solid tumor effector chemotherapy agents can be more accurately achieved via narrowing on the specific 
pharmacokinetic parameters - in this case, water solubility - thus cutting considerably on the cost and time needed to 
bring similar drugs into clinical utility. 
 
 
Figure 6:  Screen-Shot Of The Knowitall® Predictor Profileittm For Taxol® Is Represented Below, And The Required 
Water Solubility Data Can Be Extracted From These Predictions 
 
Matulane
®
 
 
Hematopoietic malignancies, in their advanced stages, tend to involve other solid organs outside the lymph 
nodes and marrow spaces. As such, they need to be targeted in the intravascular and extravascular compartment 
including across the blood brain barrier. Chemotherapeutic agents that are used in these settings, such as Matulane
®
 
for advanced stage Hodgkin’s Lymphoma, are chosen for their specific pharmacokinetic parameters, notably their 
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aqueous solubility. Due to its good solubility at gastric pH as well as at plasma pH, Matulane
®
 is the perfect 
candidate. It is can be readily absorbed when given orally, thus there is an ease of administration. Completely 
soluble in blood, cross the blood brain barrier, it thus has the ability to be readily bioavailable in all potential 
compartments. The kidneys, decreasing the amount of potential toxicities, also can readily eliminate it. All these 
characteristics are mainly due to its water solubility. The accuracy by which our computer model was able to predict 
its solubility is documented in Figure 7. Mirroring the utility and applicability of our findings on formulating similar 
drugs, agents with similar solubility can be predicted with measurable accuracy using our model. Thus, in filtering 
through potential chemotherapeutic candidates with proven in-vitro clinical efficacy, our model can help in 
narrowing down the search. 
 
 
Figure 7:  Screen-Shot Of The Knowitall® Predictor Profileittm For Matulane® Is Represented Below, And The Required 
Water Solubility Data Can Be Extracted From These Predictions 
 
Nexavar
®
 
 
In formulating drugs that are intended for treatment of solid tumor with the primary metabolite or molecule 
being insoluble in aqueous solutions, a parenteral rout of administration is not very practical. The drug has to be 
administered in a continuous mode to achieve comparable results to its in vitro action, and a functional group needs 
to be added to make the whole compound water soluble. An example is Nexavar
®
, a chemotherapeutic agent used 
primarily to treat renal cell carcinoma and unresectable hepatocellular carcinoma. The active ingredient, sorafenib 
tosylate is a kinase that achieves its steady state blood level after seven days of continuous oral administration of 
400 mg twice daily. This needs to be maintained for a total of 28 days to produce its optimum inhibitory effect on 
tumor growth. Thus the best way to achieve this is through the oral route - a potential problem with an insoluble 
molecule like sorafenib - a parameter that we were able to predict with high comparable accuracy using our 
computer model. We were also able to predict the solubility at gastric pH and plasma pH after pairing the active 
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ingredient with the functional group (Figure 8). It also follows that the applicability of our model is of practical 
utility in formulating similar drugs with specific clinical/pharmacokinetic parameters. 
 
 
 
Figure 8:  Screen-Shots Of The Knowitall® Predictor Profileittm For Nexavar® Is Represented Below, And The Required 
Water Solubility Data Can Be Extracted From These Predictions 
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Gleevec
®
 
 
While the above mentioned kinase is insoluble at acidic, as well as basic pH, and can only be clinically 
useful if a functional group is added, other kinase inhibitors, such as Gleevec
®
 (Imatinib), lends itself perfectly due 
to its excellent solubility at low pH and very low solubility at neutral pH. Gleevec
®
 is very effective in treating 
Philadelphia chromosome positive hematologic malignancies such as CML and ALL. It can also be used in other 
sarcomas such as GIST. Being very soluble at low pH, it can be given orally with excellent absorption, yet with its 
insolubility at blood pH, it can attain therapeutic levels fast, get slowly eliminated and have a high volume of 
distribution. As illustrated below (Figure 9), our model accurately predicts this biphasic solubility as a function of 
the pH. This also lends itself easily to pre-experimental phases in selecting drugs that are intended to be similarly 
administered with a comparable eventual volume of distribution. 
 
 
Figure 9:  Screen-Shots Of The Knowitall® Predictor Profileittm For Gleevec® Is Represented Below, And The Required 
Water Solubility Data Can Be Extracted From These Predictions 
 
Doxil
®
 
 
Perhaps the best practical application for our model is in formulating targeted therapy whereby effector 
agents are known for their in-vitro action, yet their solubility prohibits effective delivery to the target organs/tumors. 
Having the ability to accurately predict the behavior of the major molecule/metabolite at different pH levels make it 
possible to manipulate the drugs in its pre-experimental form, thus giving us an edge in predicting the final product 
behavior at the given pH. This concept is best-illustrated by applying our computer model to a drug like Doxil
®
, a 
parenteraly administered chemotherapeutic agent used to treat ovarian cancers and AIDS-related Kaposi’s Sarcoma. 
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The active ingredient is Doxorubicin, which is encapsulated in Doxil
®
 in a liposome lipid bilayer. Studies have 
shown that, in contrast to Doxorubicin, Doxil
® -
 and due to the liposome delivery system - has a very low volume of 
distribution confined to the vascular fluid volume. This gives this agent a targeted cytotoxic effect within the 
neovascularization inherently pronounced in ovarian carcinoma and Kaposi’s sarcoma. If we apply our prediction 
algorithm to Doxil
®
, it shows its stable low solubility at plasma pH and is even less soluble at higher pH, up to 
extremely high pH where the lipid bilayer is broken and exposing the soluble Doxorubicin. This is exactly mirrored 
clinically and correlates accurately to the predicted values (Figure 10). This parameter insures the stability of the 
delivery system until targeted areas are reached, releasing the active ingredient. Our model’s applicability in 
formulating such drugs thus transcends its in-silico applicability into experimental utility. 
 
 
Figure 10:  Screen-Shots Of The Knowitall® Predictor Profileittm For Doxil® Is Represented Below, And The Required 
Water Solubility Data Can Be Extracted From These Predictions 
 
CONCLUSIONS 
 
Even though the FDA periodically updates its guidance relevant to the disclosure of risk information in 
prescription drug product labels and inserts, no consumer-information standards have been implemented for drugs 
(Shrank and Avorn, 2007). A lack of pH-sensitive pharmacokinetic information hinders the ability of providing 
quality clinical care. To overcome such challenges, we have definitively shown that in silico tools could be 
employed to predict the potential pH-sensitive biological and biochemical interactions between the molecular 
chemical drug entities and targets in the patients. The implementation of the web application for clinicians, 
researchers, and healthcare providers to add real-world data is available at http://annotation.dbi.udel.edu/CancerDB/. 
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